Larazotide
Overview
A synthetic octapeptide derived from Vibrio cholerae zonula occludens toxin that acts as a tight junction regulator. Larazotide acetate modulates intestinal permeability by preventing zonulin-mediated opening of tight junctions between enterocytes.
Mechanism of Action
By reducing paracellular permeability, it aims to prevent gluten peptide translocation across the intestinal barrier in celiac disease, reducing the immune-mediated inflammatory response triggered by gluten exposure.
Research Summary & Key Findings
Phase 2b trial showed significant reduction in celiac disease symptoms and improved lactulose-to-mannitol ratio (a marker of intestinal permeability) in patients on a gluten-free diet exposed to gluten challenge (Leffler et al., Gastroenterology, 2015). Phase 3 trials ongoing as adjunctive therapy for celiac disease. If approved, would be the first pharmacological treatment for celiac disease beyond dietary gluten avoidance.
Clinical Status
Larazotide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Larazotide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Larazotide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Larazotide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsStart Your Consultation
Get an AI-proposed Larazotide protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Larazotide.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.